Buchalter resigns as Enzon CEO

Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) said Jeffrey Buchalter resigned as CEO and a director. He is replaced by an executive committee that is chaired by Alexander Denner, who is chairman of Enzon's board, and includes directors Richard Mulligan and Rolf Classon. The committee also will serve as the search committee for a new CEO. Denner, a representative of investor Carl Icahn, was appointed non-executive chairman of the drug delivery, infectious disease and cancer company last year. Mulligan is also an Icahn representative. At Dec. 31, 2009, Icahn held 2.8 million shares of Enzon, or 6%, based on 45.3 million shares outstanding (See BioCentury, Nov. 16, 2009). ...